Pappas Capital LLC
04/16/2008 | Press release | Archived content
MethylGene initiates Phase 1 clinical trial for its multi-targete...
News | 04. 16. 2008
Mirati Therapeutics
MGCD265 Targets c-Met, VEGFs, Tie-2 and Ron Receptor Tyrosine Kinases
Initial Compound from Portfolio of Potent Multi-targeted Kinase Inhibitors
Montreal, Quebec. April 16, 2008 - MethylGene Inc. (TSX:MYG) today disclosed preclinical data for MGCD265, an oral, multi-targeted (c-Met) kinase inhibitor for cancer that targets the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. The data were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
Pappas Capital LLC published this content on April 16, 2008, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]